Conferences - Results from #300

ESMO 2024: Efficacy of Talazoparib and Enzalutamide in mCRPC Patients Previously Treated with Androgen Receptor Pathway Inhibitors or Docetaxel – Post Hoc Analysis from Both Cohorts in TALAPRO-2 Study September 14, 2024

ESMO 2024: Updated Efficacy Profile of the Double Antibody Drug Conjugate (DAD) Phase I Trial: Sacituzumab Govitecan plus Enfortumab Vedotin in ≥ Second Line in Metastatic Urothelial Carcinoma (mUC) September 14, 2024

ESMO 2024: Phase II Randomized Double-Blind Trial of Axitinib +/- PF 04518600, an OX40 Antibody after PD1/PDL1 Antibody Therapy in Metastatic Renal Cell Carcinoma – Final Analysis September 14, 2024

ESMO 2024: Results from the Quick Efficacy Seeking Trial (QuEST1) Arm Combining BN-Brachyury (BNVax) + Bintrafusp Alfa + Nogapendekin Alfa Inbakicept-Pmln (N-803) in Castration-Resistant Prostate Cancer September 14, 2024

ESMO 2024: Factors Influencing Clinical and Biological Response in Patients Treated with [177Lu]Lu-PSMA-617 Under France's Early Access Program September 14, 2024

ESMO 2024: PSMA-targeted Radioligand Therapy with 131I-LNTH-1095 Plus Enzalutamide versus Enzalutamide Alone in Chemotherapy-naïve Patients Whose Piflufolastat F 18-avid Metastatic Castration-resistant Prostate Cancer Progressed on Abiraterone: ARROW September 14, 2024

ESMO 2024: Prospective Evaluation of BCG Unresponsive Bladder Cancer CIS Identifies Genetic Mechanisms of Immunotherapy Resistance and Targeted Therapy using an Ultra-Sensitive Next Generation Sequencing Minimal Residual Disease Assay September 14, 2024

ESMO 2024: Total and Regional Changes in Body Composition in Metastatic Hormone-Sensitive Prostate Cancer Patients Randomized to Receive Androgen Deprivation + Enzalutamide +/- Zoledronic Acid. the BonEnza Study September 14, 2024

ESMO 2024: Association of the Lipid Biomarker, PCPro, and Clinical Outcomes in the ENZAMET Trial (ANZUP 1304) September 14, 2024

ESMO 2024: Final Safety and Efficacy Analysis of RaLu: 177Lu-PSMA Therapy in Patients with Prior Radium‑223 September 14, 2024

ESMO 2024: Real World Efficacy of 1st Line Nivolumab plus Ipilimumab and Its Practical Predictive Biomarkers in Advanced Renal Cell Carcinoma: First Analysis from RENOIR Study (KCSG GU22-13) September 14, 2024

ESMO 2024: How to Manage Patients with Durable Response on Systemic Therapy? Optimal Therapy Duration and Role De-Escalation? September 14, 2024

ESMO 2024: Prostate Cancer Working Group 4 Preliminary Criteria Using Serial PSMA PET/CT for Response Evaluation: Analysis from the PRINCE Trial September 14, 2024

ESMO 2024: CaboPoint: Final Results from a Phase 2 Study of Cabozantinib After Checkpoint Inhibitor Combinations in Patients with Advanced Renal Cell Carcinoma September 14, 2024

ESMO 2024: Building on Standard Therapies: Novel Agents and Promising Combinations in Urothelial and Renal Cell Carcinoma September 14, 2024

ESMO 2024: Circulating Versus Tissue-Based Biomarkers September 14, 2024

ESMO 2024: Opevesostat (MK-5684/ODM-208), an Oral CYP11A1 Inhibitor, in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Updated CYPIDES Phase 2 Results September 14, 2024

ESMO 2024: What Is the Role of Rechallenge with the Same Class of Agents in Advanced Disease? September 14, 2024

ESMO 2024: SOGUG-NEOWIN: Erdafitinib Monotherapy and Erdafitinib and Cetrelimab as Neoadjuvant Treatment in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer and FGFR Gene Alterations September 14, 2024

ESMO 2024: Novel Therapeutic Approaches for ARPI-resistant Disease September 14, 2024

Page 16 of 594